Every year the Cure Alzheimer’s Fund (CAF) Research Consortium members get together with the Board of Directors to discuss their respective research projects, refine their strategy, and leave with a clear mission. This year was no exception.
On Feb. 5, 30 individuals gathered in San Diego for a full day of scientific discussions. The scientists presented their latest research to their peers, and followed up with an insightful discussion. “One of the things that often comes out of the presentations is that people in the room offer to work with the presenter on his or her project, or recommend someone who is working on something similar,” said Tim Armour, President and CEO of CAF. “While researchers tend to work on individual projects, this type of forum gives them an opportunity to learn from and collaborate with each other.”
After the presentation, the group participated in a general strategic discussion about what the Consortium should focus on going forward from a research perspective. The meeting also compiled a list of fellow scientists for potential recruitment to the “Genes to Therapies” (G2T) project, a highly focused initiative that targets all the genes in Alzheimer’s pathology and pairs them with individual researchers for study.